| 标题 |
Minimum effective low dose of antithymocyte globulin in people aged 5–25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet 作者:Chantal Mathieu; Julie Wych; Emile Hendriks; Lisa Van Ryckeghem; Timothy Tree; et al 出版日期:2025-09-01 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)